BioRestorative Therapies, Inc. (BRTX)

From the record

BioRestorative Therapies, Inc.'s filings since 2017 show 19 warning events of 6 kinds: a bankruptcy or receivership notice (8-K item 1.03, 5 times, the latest 2020-11-20); a debt default or acceleration notice (8-K item 2.04, 2 times, the latest 2020-03-20); a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2026-08-25); a warning not to rely on past financial statements (8-K item 4.02, the latest 2024-05-24); an auditor change (8-K item 4.01, 5 times, the latest 2026-09-10); a late-report notice (Form NT 10-K or NT 10-Q, 4 times, the latest 2026-08-14) (its current reports).

From the record

BioRestorative Therapies, Inc.'s 9 filed years say what it did: revenue went from $81 thousand in fiscal 2017 to $360 thousand in fiscal 2025, up 20.5% a year; it rose in 5 of 8 years; the deepest fall was 65% from fiscal 2019 to fiscal 2021; net income was positive in 0 of 9 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, BioRestorative Therapies, Inc. lost about 3992 cents for every dollar of shareholders' money, and gross profitability: its products earned about 8 cents per dollar of everything the company owns. Leverage: it owed about 91 cents per dollar of assets, and net share issuance: its share count grew 15.8% over the year (the filed statements).

From the record

BioRestorative Therapies, Inc.'s standing among 10 graded names in its industry family: revenue of $360 thousand in fiscal 2025 ranks in the bottom 6% by size; a net margin of -3959.4% ranks in the bottom 15%; revenue growth of 44.3% a year over the last 3 filed years ranks in the top 15% (its annual reports).

From the record

BioRestorative Therapies, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Alstodt, Lance (President, CEO, COB, as filed), filing under that title since 2020-11-24, 6 years (top 31% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 5 months (bottom 7%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 7 people in charge now (bottom 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

BioRestorative Therapies, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $2 million against no long-term debt tagged leaves 37% of its assets as net cash, top 5% of its family; cash from operations less capital spending is -3031.7% of revenue (bottom 5%); a gross margin of 93.4% (top 6%); research spending of 2806.4% of revenue (top 10%) (its annual report).

From the record

BioRestorative Therapies, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 44.3% a year over the last three filed years against 20.5% over all 9, speeding up (top 5% of its family); the newest year grew -10.3% (bottom 25%); research spending grew 42.2% a year (top 12%); capital spending grew -24.1% a year (bottom 25%) (its annual reports). BioRestorative Therapies, Inc. reported 2 product lines in fiscal 2025: Product at $300 thousand (83%), Royalty at $60 thousand (17%); 0 of 2 grew against the year before (its annual report).

From the record

BioRestorative Therapies, Inc.'s newest year against its own record: revenue of $360 thousand in fiscal 2025 came in 51% below the $733 thousand its prior three years' pace pointed to (bottom 15% of its family); net income of $14 million against a prior three-year average of $11 million (bottom 25%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 15%) (its annual reports).